Jubilant Life Sciences has received an approval for acquisition of 18,66,20,000 12% Optionally Convertible Non-cumulative Redeemable Preference Shares of Rs 10 each of Jubilant Biosys at par aggregating to Rs 186.62 crore, subject to applicable laws. The board of directors at its meeting held on February 07, 2017, has approved for the same.
Jubilant Life Sciences is engaged in manufacturing and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.
